Did you ever stop to consider how QUAN will actually follow through with this glorious business plan with $1800 in cash, an accumulated deficit of $27 million, a working capital deficit of $1.3 million, a string of existing toxic convertible debt looming to be converted, and a single employee who lacks any experience in the robotics industry??

"And who cares about dilution if you don't have money to survive? " - apparently AMBS management has no concern about dilution:

O/S shares = 107.4 million
Outstanding convertible debt potential and other obligations:
$230k due at end of 2012 = about 53 million shares
$41k to MMRI convertible to preferred stock
$500k note to 10 investors - currently in default
$23k remaining on Dec. 2011 convertible note
$169k remaining on Oct-Mar convertible notes
$54.5 remaining on Mar 2012 convertible note
$245k remaining on Jan convertible note
$22k to Neurotrophics
$150k to Dr. Herschkowitz
500k stock options (fully vested) issued in November to a consultant
Pending lawsuit for Peter Freeman for financial overhang on convertible debt
10.7 million share stock option plan

I suppose you are correct, issuing several more tens of millions of shares to the already overbloated O/S is just background noise as one more to add to the stack....

Hey, 20K can buy 2,000,000 shares right now. - the fact of the matter is that assuming RBCC is not delinquent on their previous obligations, the $20k is already gone.

RBCC will not be buying AMBS shares at market price - the likely scenario is that they would infuse capital at a significantly steeply discounted rate to market pricing, resulting in further dilution for AMBS. Not exactly good news for shareholders in light of existing dilution already executed.

Seems to have money for AMBS - HUH?

RBCC(D)'s latest 10-K filing: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8719222

Cash = $20k

The Company incurred a net loss of $555,211 during year ended March 31, 2012 and had net cash used in operating activities of $195,095 for the same period.

The Company purchased an equity stake in N3D. The total purchase price of $249,826 will be paid by making weekly payments of $5,000 until fully paid. Through March 31, 2012, they have made payments totaling $15,000 to N3D.

CEO Patrick Brown receives $5500 per month for his part time services (he is also CEO of OMVS).
Mr. Foxwell is being compensated at a rate of $2,500 per month.

The above nets to $28k per month in commitments.

At this burn rate, the company is already out of cash.

Furthermore, the Company anticipates it will require around $200,000 to sustain operations and implement its business plan over the next twelve months. Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

No matter how good the news, shorters short more. - this has nothing to do about shorting, just setting the facts straight.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77848049

HA HA HA! good one....a press release stating to extend the letter of intent to possibly, maybe enter into negotiations for a possible deal, after they finish their due diligence, to provide funding and expertise for an unknown number of projects - WHEW - and I thought that deal was dead!. RBCC continues to have no such expertise or funding to give, so the games continue....

I thought the male enhancement drug schtick was "last year's" scam (along with the ones from Nigeria) - are people still falling for this BS?

AMIN to the greys?: http://www.otcbb.com/asp/dailylist_detail.asp?d=07/23/2012&mkt_ctg=OTCBB

Ineligible for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11

Curious that the filing did not note whether Haim Silber has also departed or not? Haim seem to have trouble complying with his felony probation: http://law.justia.com/cases/texas/first-court-of-appeals/2012/01-11-00346-cr.html

You mean the TSX has standards?

Maybe they are moving to the TSX exchange....lol....

DOMK stated today that it has retained the services of RBL Communications ("RBL") to manage a complete social media program. RBL is stated to be a "full service media solutions provider that develops comprehensive online marketing campaigns for small-cap companies" listed on the Toronto Stock Exchange (TSX).

RBL lists these TSX companies which show a consistent (bad) track record as their "success" stories (52 week stats):

AZX: High $0.17, Low $0.03, 82% loss
DAN: High $2.48, Low $0.80, 68% loss
AWH: High $0.17, Low $0.02, 88% loss
DDI: High $0.35, Low $0.02, 94% loss
FV: High $0.09, Low $0.01, 89% loss
HMI: High $0.155, Low $0.035, 77% loss
ICG: High $0.46, Low $0.18, 61% loss
PEN: High $0.315, Low $0.07, 78% loss
SRC: High $0.40, Low $0.045, 89% loss
TAJ: High $0.21, Low $0.045, 79% loss
TAK: High $0.305, Low $0.04, 87% loss

RBL notes specifically a "success story" ( http://www.rblcommunications.com/success-stories ) on KWG Resources that had a huge increase in social media hits on Facebook after they launched their campaign. Unfortuneately, the stock price has tumbled from $0.14 at the time they started marketing down to its current level of $0.06 (57% loss)...

DOMK has apparently picked this Toronto Stock Exchange media solutions provider to gain further international exposure at the Olympics....it is unclear if DOMK intends to join the TSX exchange in order to share in this success....

Shorters?? Seriously? You have 9 trades (~$700) today - hardly worth the price of admission/commission....

The good news, not much selling....

DOMK files to correct that it registered, withdrew, and reregistered 1 million shares...again....I think.....

On May 29, 2012, Domark International, Inc. ("DoMark") mistakenly filed Post-Effective Amendment No. 1 to its Registration Statement on Form S-8 filed on May 1, 2012. The Post-Effective Amendment purported to register an additional 1,000,000 shares of common stock of DoMark. DoMark is filing this Post-effective Amendment No. 2 to withdraw the 1,000,000 shares reflected in its Post-Effective Amendment No. 1. DoMark will file a new Form S-8 to register the 1,000,000 shares of DoMark common stock that were purported to be covered by Post-Effective Amendment No. 1.

"The only thing that has me curious are the larger buys today. Volume spike..was heavy." - not to rain on anyone's parade here (btw - congrats on the jump!), but let's also not get carried away. The reality is that there were only about 20 trades on about $6000 trading hands.... this was small time activity likely attributable to 90% of the posters on this board.

On a related note, I posted RBCC's last financials which show very dim prospects for any sort of financing to AMBS.

DOMK signs endorsement deal with Olympic Runner Nick Symmonds. From Nick's personal web site he states: http://www.nicksymmonds.com/about-nick/bio/

"....In an effort to bring attention to this [endorsement] issue, Nick held a 2012 eBay auction, offering the winning bidder space on his own skin. He now prominently places a temporary tattoo with the winning agency’s logo on his left shoulder when he competes."

That auction was apparently awarded to a company called Hansen Dodge Creative. It is unknown if DOMK won a 2nd ebay auction for putting their logo on his right butt cheek.....

RBCCD annual report just published: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8719222 -

There was no mention of AMBS: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77572174

RBCCD Annual Report:

Outstanding shares increased approximately 11% over the last 6 months to 595,000 shares (post 1:20 reverse split. Subsequently, on April 13, 2012, the Company issued 20,000 shares of common stock to an individual for consulting services resulting in a total of 615,000 shares currently outstanding.

RBCCD entered into an agreement to purchase 5% of the outstanding stock of N3D for $249,826, payable at $5k per week until paid off. Through March 31, 2012, the company has made payments totaling $15,000 to N3D. The company has written off the investment to general and administrative expense due to the uncertainty about whether the carrying amount is recoverable.

CEO Patrick Brown receives $5500 per month.
Mr. Foxwell is being compensated at a rate of $2,500 per month.
The company has $20k in cash reserves.

Most important information from the annual report - there is a new Beneficial Owner: Glendive Investments registered in Poland by Cambirdge Securities (owned by JT Cloud and Robert Federowicz): http://www.infocredit-online.pl/en/Company-report/KRS-392725,Activities-of-head-offices,Mazowieckie,Warszawa,Glendive-Investments-Sp-z-oo.html

In August 13, 2010, the company sold 450,000 shares of common stock to our founder, Lou Foxwell, for $0.02 per share. On October 13, 2011, Mr. Foxwell sold his shares to Glendive Investments, a Polish company, for cash proceeds of $10,000 (resulting in a net profit of $1000). So this begs the question, why did Mr. Foxwell leave so much money on the table? His 450,000 shares at current market price is valued at $558,000!!

RBCCD has two employees
RBCCD has two shareholders

RBCCD incurred a net loss of $555,211 for the year ended March 31, 2012. Net cash used by operations for the year ended March 31, 2012 was $195,095.

RBCCD earned a gross profit of $28,614 attributed to their Father Fish Aquarium division.

RBCCD recognized general and administrative expenses in the amount of $582,349 for the year ended March 31, 2012 and issued stock for services resulting in general and administrative expense of $355,000.

The company incurred a net loss of $551k for the year.

The Company anticipates it will require around $200,000 to sustain operations and implement its business plan over the next twelve months. Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

The annual report makes no mention of pending deal with AMBS.

Meanwhile, Patrick Brown's other venture he is CEO of has lost yet another 35% yesterday fading into oblivion: OMVS

Are you suggesting the CEO call to help manipulate the stock price?

agreed - however, consider how much would it cost in terms of diluting even more shares....

DOMK signs on Sean Pena to Advisory Board and agrees to give him an all expenses paid trip to the Olympics. Just curious how far that ~$6,000 in cash will go after airfair and event tickets....hopefully he has some happy meal vouchers for food....

noone11 - thank you for the data and supporting your statement. I concur that my link provided is only a snapshot in time and not necessarily indicative of real time short positions.

So here is the curious thing - normally, shorting of penny stocks requires a substantial margin requirement and requires finding the shares to short (i.e. we are not talking about illegal naked shorting) - it is generally considered not cost effective to short a stock below $0.25: http://theotcinvestor.com/how-to-short-sell-penny-stocks-121/

Even in the scenario where someone has taken on this margin call risk in the case of AMBS as suggested by you and others, wouldn't the prudent trading approach of a shorter be to not hold the position longer than a few days? By your account, this has been going on for months. My observation of stocks that have active documented shorts (i.e. go to Timmy Sykes site) is that you will see dramatic daily swings up and down as the shorts are covered - one has not seen this yet in AMBS - only a constant downward trend.

I can't argue with the data you have provided, but suggest that the more likely cause (or at a minimum a significant contribution to the trend) of the stock price drop has been the millions of shares that are a result of toxic debt conversions and shares issued for services.

"we have been receiving the reg SHO reports for over 6 months on ambs, since 10 cents all the way down to .01 their have been millions of shares short" - ok....prove it by posting the reports so we can settle the issue.

I did not know that 110,000 shares on 6 trades (roughly $1000) was considered a "big block"?......

There does not appear to be much information out there on CTXE - the financials are very stale (2009 being the latest): http://www.otcmarkets.com/financialReportViewer?symbol=CTXE&id=29817

There is significant questions surrounding their oil & gas assets as to who really owns them at this time, as well as no information from the company regarding their current production status (including the Big Canyon prospect which apparently has working interests sold to FTTN).

From the 2009 annual report:
Cantex has an accumulated deficit of $1.8 million

Beneficial owners - not stated/unknown

Steve Plumb - same guy that brought you ADBI to your AMIN for a seat on the Board.

Steve Plumb has a history of involvement with the same guys running FTTN (namely Kathleen Delaney, JT Cloud, Robert Federowicz). FTTN noted a few months ago that they were looking to acquire Bedford Operating Company (BFDE). While researching BFDE, I noticed that there is a great deal of confusion as to who really owns BFDE as they appeared to have had a deal previously to merge with CTXE (which brings us full circle back to this board) and now share the same website.

So it is interesting to me that someone (perhaps connected thru AMIN?) has directed you here as there is a thread of commonality going on - perhaps I am a little paranoid, but care to share who has sent you this way?

"someon etold me to look!" - was it Steven Plumb (LOL)?

Has anyone heard about how the LOI's are coming along after having received ".....inquires from several national retailers requesting information on placing bulk orders of the Company’s SolaPad and SolaCase products"....and taking their "first step of our strategy to build on the Company's market position quickly and decisively to benefit all shareholders" - sales ought to be flying off the shelf now, right?: http://finance.yahoo.com/news/domk-solapad-ipad-accessory-sales-123000343.html

IPO$ - from the latest financials:

"In April 2010, the Company was awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (“MJFF”). Pursuant to the MJFF grant, the Company performed research related to comparison and analysis of certain genes in rodent models of Parkinson’s disease. The grant provided for the reimbursement of expenses as incurred up to a maximum of $370,716, payable in two installments with targeted payments in April 2010 and October 2010, and it established two milestones. During the three months ended March 31, 2011, the Company achieved certain milestones and received payment and recorded revenue of $178,308. To date, through March 31, 2012, the Company has received a total of $370,716 from the MJFF."

The rat tests are complete - money was received and spent - no money remains.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77328456

Exactly....not a very good pump job for the shares issued.

I found this statement particularly self serving by the paid tout: http://tomorrowsbluechips.com/wp-content/uploads/2012/07/AMBS-Research-Report.pdf

"We believe based on this information Amarantus is a great target for lucrative partnerships and with recent short action pounding the stock down to below $.02, the potential for a short-­-term short squeeze is possible. We believe that the stock could trade back in the old range of $.10-­-$.15 with recent good news and potential short covering."

The reality, is that there is little (only 2499 shares as of 6/29) to no shorting of this stock occuring - see the report here: http://www.otcmarkets.com/stock/AMBS/short-sales

As I have pointed out the reason for "pounding the stock down to below $0.02" (now $0.01) is for the simple fact that there are a ton of convertible debt shares that have flooded the market (this is in addition to the 2.5 million restricted shares issued to this paid tout): http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77328456

Regarding the paid tout by Tomorrowsbluechips.com, here is my take:

The analyst report states: "The most extreme example includes GlaxoSmithKline's (GSK) $57M buyout of Genelabs (GNLB) for an astounding premium of over 400% for the latter's hepatitis C clinical development assets" - yet without any basis for supporting their prediction, they tout a target price for AMBS at $0.10 to $0.15 - an astonishing potential increase of 669% to 1054% from the stated stock price of $0.013 (currently at $0.0099) - several fold above their "extreme" example for GNLB.

I suppose this is not so surprising considering their disclaimer which states: "TomorrowsBlueChips parent company Seraphim Holdings llc has been compensated for coverage/awareness efforts the following companies: Amarantus BioSciences Inc. AMBS) – 2,319,999 restricted shares and 50,000 free trading shares for 6 months services expiring 5/24/12. 75,755 AMBS open market purchase, which position has been closed. AMBS.BB compensation 225,000 restricted shares for 30 days marketing / awareness services on May 9 2012."

What is curious is that their services appear to have expired on 5/24/12 - which leads me to believe that the remaining 2.5 million restricted shares have now come off of restriction and they are pumping this one more time to cash out.

Suppose they get enough interest to fund the clinical trials - at what toxic debt conversion rate would be acceptable to consummate the funding at without further killing the company?

It's a rhetorical question of course....in my opinion, the best outcome for AMBS is to liquidate their technology to settle open and pending lawsuits (or to someone that has the means to bring it to fruition), then sell what remains of the shell.

You are correct - the 60 day period has passed without any word from either company.

Under the terms of the LOI, the companies had agreed to a 60-day option period during which they would negotiate a possible deal for RBCC to provide funding and expertise toward the development and marketing of one or more of Amarantus’ projects.

Funding
RBCC's latest financials (http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8409247 ) show they have $14k in cash - will this be enough to fund clinical trials?

Expertise
RBCC is an aquarium supply house and coral farm (their only source of revenue) that is pretending to somehow be a BioScience company. None of the two employees have any "expertise" to offer to AMBS as part of the contribution towards development of one (or more) of AMBS' projects.

This "possible" deal is never going to happen - to wish otherwise is simply naive.

"Could take a few days getting thru these massive blocks..." - agreed, someone would need to take a few days to break into their piggy bank to clear a 240,000 block x $0.014 = $3360......

I can't help you out if you fail to read through the posts here and on GTSO, FTTN, RBCC, NTRR and elsewhere - or even just the financials.

Robert has no robotics experience nor any connections in Poland (aside from the entities he set up with JT Cloud to hide the identity as being the beneficial owner). QUAN has no assets, no robotics, no staff, nothing...nada...zilch.

If you wish to play the stock as a daytrader, I suppose that is fine. Pretending this is a real company with real prospects - are you that naive? Please read the financials and get back to us with any glimmer of hope for this POS you can find.

"...then this stock will one day be very rewarding either from a buyout or from AMBS getting funding to advance their clinical trials."

I would think that most would agree that a buyout isn't going to happen without clinical trials. Regarding funding to advance the clinical trials, what steeply discounted convertible stock price would you consider rational for a venture capitalist to risk considering the stock has gone from $1.50 to $0.01 in the last year? How much money would that take to perform the trials?

"This is a one-cent stock in the Bio Tech Sector" - agreed, and 2 months ago it was 90% higher at $0.10, and one year ago it was 150% higher at $1.50 - at what point does HOPE turn into HOPE-LESS? $0.001? $0.0001?

Whether it is a pure pump or spending several million dollars to bring their product to market, the company would still need to issue millions of shares to pay for such a rally. The time to have done that would have been last summer or even as late as November 2011 when the stock appeared to be having a mini-rally. Where was management at then to make that rally continue? Why would an investor have any faith that they could pull it off now?

Unfortunately, the facts do not support the theory of shorters pushing the stock down - this link shows nearly zero activity: http://www.otcmarkets.com/stock/AMBS/short-sales

Holding out hope that a PR firm will somehow rescue this stock slide is simply wishful thinking - irregardless of the validity of their promising technology. The reality check is the following:

Cash on hand = $148
Revenues = $0 (latest quarter)
Costs = $1.4 million (latest quarter)
Liabilities = $3.9 million+
Outstanding shares = 107.4 million

MJFF Grant money left = $0

The selling that you are seeing is most likely related to these series of convertible notes:

Convertible debt = $230k - convertible at 33% of then existing share price (at current price of $0.013, that would equate to roughly 53 million share dilution ) - these series of notes come due starting the end of 2012. This does not include the $41k of convertible note to MMRI for Preferred Stock.

The company states another $500k note to 10 investors which was amended for the note holders to have warrant coverage equal to 100% of the note principal at an exercise price equal to 100% of that to outside investors in the closing of the next equity financing of $1,175,000, but not to be less than $0.60 per share. The warrants expire five years from the date of the next equity financing closing. We are currently in default on these notes.

During the twelve months ended December 31, 2011, the Company issued convertible promissory notes to various investors for aggregate proceeds of $90,000. During the three months ended March 31, 2012, $67,000 of these convertible notes converted to Company Common shares (leaving $23k remaining to be converted).

During the period October, 2011 through March 31, 2012, the Company issued convertible promissory notes to various investors for aggregate proceeds of $168,750.

During the three months ended March 31, 2012, the Company issued two convertible promissory notes to one investor totaling $54,500. Principal and interest on these convertible notes accrue at the rate of 8% per annum.

In January, 2012, a vendor convertible their trade account to convertible promissory notes for the amount due them at the time of the note plus future billings, amounting to $244,988.

The company stil owes Neurotrophics $22k and Dr. Herschkowitz $150k.

Effective November 1, 2011 the Company entered into a consulting agreement where the consultant is to receive a stock option for common stock of 500,000 shares, fully vested.

Notwithstanding the above financial overhang of convertible debt, on January 6, 2012 the Company was served a summons regarding the filing of a lawsuit (Complaint for Breach of Contract, Specific Performance and Common Counts) against the Company by a former consultant to the Company, Peter Freeman v. Amarantus BioSciences, Inc.

In addition the Company is in default on payment of certain Convertible Notes that were due as of December 6, 2011 and is also late with regard to making payments to various trade account vendors for goods and services received, of which some accounts are currently with collection agencies and could possibly result in lawsuits with the Company.

The company also has a stock option plan where over 10.7 million shares can be issued (some of which have already been granted)

The hope that RBCC will somehow provide funding is also wishful thinking.

LONGINGFORWOOD, Fla., Feb. 30, 2012 (BUSINESS WIRE) -- SolaWerks, a wholly owned subsidiary of DoMark International disclosed today seven-time 1972 Olympic Gold Medalist, Mark Spitz, will be coming out of retirement to challenge Michael Phelps at the London Olympics using SolaWerks' newly patented SolaFin products (http://solarbathingsuit.com/sitebuildercontent/sitebuilderpictures/Solar_Powered_Women.jpg ) that are proven to boost the swimmer's edge in competition. Spitz commented that if he can achieve maximum solar charging in the center lane of the pool, he can shave at least 2.3 seconds off of Phelp's World Record times. Spitz also believes that if the awards ceremony is conducted at exactly 2:31pm at the peak apex of the sun, that his solar chargers will be able to actually make his gold medal glow without ever having to charge again.

The first SolaFin units have been shipped to customers who pre-ordered the unit from the SolaWerks' ecommerce website. The Company anticipates its next shipment of SolaFins to arrive just in time for Spitz's Olympic prelim races. Orders from the Company's website will resume as soon as the Company has confirmation that the units have cleared London customs and are on route to its fulfillment center.

The evolutionary SolaFin is an ever-charging solar and battery system that fits all versions of Speedo Swimsuits. The SolaFin provides hours of power from sun and battery. The SolaFin can be purchased directly on the Company's website at http://www.solawerks.com/whatascam.html

http://2.bp.blogspot.com/_7RJ9kf0mJfc/TK_C0ATN5xI/AAAAAAAAAZ0/uBcgJeKYo3A/s1600/Mark+Spitz+Olympic+Gold+Medals.jpg